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Background: Vitamin K, as a cofactor in the gamma carboxylation of certain glutamic acid (Gla) residues, has been
related to glucose metabolism and insulin sensitivity. Osteocalcin, also known as bone γ-carboxyglutamic acid,
increases β-cell proliferation as well as insulin and adiponectin secretion, which improve glucose tolerance and insulin
sensitivity. Thus, the purpose of the present study was to examine the possible role of adiponectin as a mediator of
glucose homeostasis following phylloquinone supplementation in premonopause women with prediabetes.
Methods: Eighty two women were randomized to consume vitamin k1 supplement (n = 39) or placebo (n = 43) for
four weeks. Participants in vitamin K1 treatment group received one pearl softgel capsule containing 1000 micrograms
phylloquinone while the placebo group received one placebo capsules daily for four weeks. The Blood samples
were collected at baseline and after a four-week intervention to quantify osteocalcin, adiponectin, leptin and
relevant variables.
Results: Phylloquinone supplementation significantly increased serum adiponectin concentration (1.24 ± 1.90
compared with −0.27 ± 1.08 μg/ml), and did not alter total osteocalcin (0.50 ± 4.11 compared with 0.13 ± 1.85 ng/ml)
and leptin (−0.29 ± 8.23 compared with −1.15 ± 5.25 ng/ml) compared with placebo. Adjustments for total osteocalcin
and adiponectin using analysis of covariance (ANCOVA) did not affect the association of glycemic status with related
variables.
Conclusions: In conclusion our study demonstrated that phylloquinone supplementation improved glycemic status in
premonopausal prediabetic women independent of adiponectin.
Trial registration: This trial was registered in Iranian Registry of Clinical Trials with ID number of IRCT2013120915724N1.
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Vitamin K is a fat-soluble vitamin that functions as a co-
factor in the gamma carboxylation of certain glutamic
acid (Gla) residues of vitamin K dependent proteins such
as osteocalcin [1]. Studies in animal models showed
osteocalcin (OC), an extracellular matrix component se-
creted by osteoblast in the bone, to be the mediator of
energy metabolism in bone, pancreas and adipose tissue.
In addition, OC in its undercarboxylated form (ucOC)
also enhanced insulin sensitivity by up-regulating adipo-
nectin expression in adipose tissues [2,3]. Also, Circulat-
ing undercarboxylated osteocalcin is an index of the
vitamin K status decreases in response to vitamin K sup-
plementation [4]. Several epidemiological studies have
examined the association of vitamin K intake and gly-
cemic status and insulin homeostasis. Higher intake of
vitamin k also vitamin k supplementation has been asso-
ciated to reduction in insulin resistance and improved
glycemic status [5-10]. These findings are in contrast to
some other studies which, based on animal models, an-
ticipate reduction in ucOC levels by increasing vitamin k
intake and hence results in adverse effects on glycemic
status. Therefore, it is likely that vitamin K exerts its in-
fluence on glycemic status through other mechanisms.
Therefore, in this study the effect of vitamin K supple-
mentation on osteocalcin and adiponectin and conse-




A randomized, double-blinded, placebo controlled clin-
ical trial was designed conducted over a total period of
four weeks. This clinical trial was approved by the Ethics
Committee of Ahvaz Jundishapur University of Medical
Sciences. Written informed consent was obtained from
all study participants. Premenopausal women with diag-
nosed prediabetes with ages 22 to 45 years and body
mass index (BMI) of 18.5 to 30 kg/m2 were eligible for
the study. Subjects were recruited based on the results
of a standard 75-g Oral Glucose Tolerance Test (OGTT)
at screening (blood drawn in the 0 and 120 min), ac-
cording to the American Diabetes Association criteria
[11]: Predibetes (PDM) was diagnosed according to the
criteria established by the American Diabetes Associ-
ation, i.e., impaired fasting glucose (IFG) (100 < fasting
plasma glucose (FPG) < 126) or impaired Glucose test
(IGT) (140 < glucose120 min <200).
A total of 82 prediabetes women met the inclusion cri-
teria. None of the subjects suffered rheumatic, thyroid,
parathyroid, kidney, or liver disease, pregnancy, lacta-
tion, menopause and drugs known to influence glucose,
vitamin k and bone metabolism like insulin and glucose,
lipid-lowering drugs, warfarin, corticosteroids, vitaminand mineral supplements within six months. Overall, 82
women were randomized to consume vitamin k1supple-
ment (n = 39) or placebo (n = 43) for four weeks. Partici-
pants in vitamin K1 treatment group received one pearl
softgel capsule containing 1000 micrograms phylloquin-
one (DSM Nutritional Products, Inc, Switzerland) while
the placebo group received one placebo capsules (Barij
Essence Co. Iran) daily for four weeks. Placebo capsules
were similar in color, shape, size appearance, and pack-
aging and were indistinguishable for participants and in-
vestigators. The participants were asked to maintain
their habitual food consumption, body weight and phys-
ical activity pattern throughout the study and not to
consume any supplements other than the one provided
to them by the investigator. Dietary intake was assessed
using a three-day food record consisting of three non-
consecutive days, including two week days and one
weekend day. The dietary records were based on esti-
mated values in household measurements. To obtain nu-
trient intakes of participants on the basis of these 3-d
food diaries, we used Nutritionist IV software (First
Databank) modified for Iranian foods. The short form of
IPAQ consists of seven questions assessing the fre-
quency and duration of participation in vigorous, moder-
ate and walking activity and the time spent sitting
during the last week was used to determine physical ac-
tivity levels [12]. The Persian translation of this ques-
tionnaire has previously been validated [13].
Assessment of variables
Body mass index and body fat were measured before
and after the intervention. Body weight was measured to
the nearest 0.1 kg after overnight fasting, without shoes
and wearing minimal clothing, by the use of a digital
scale (Seca). Height was measured to the nearest 0.1 cm
by using a non-stretched tape measure (Seca). BMI was
calculated as weight in kilograms divided by height in
meters squared (kg/m2). The body fat was measured by
OMRON BF 306 (Dalian, China) body fat monitor using
bioelectric impedance. The Blood samples (10 ml) were
collected at baseline and after a four-week intervention.
After an overnight fast, 75 g OGTT was given to each
subject between 8 a.m. and 10 a.m. Plasma glucose was
determined at times 0 and 120 min after OGTT on the
same day. Then the remaining separated serum stored
at −70 C before analysis in the laboratory of Ahvaz
Jundishapur University of Medical Sciences. Serum car-
boxylated and undercarboxylated osteocalcin (cOC and
ucOC) were measured blood serum using Takara Bio
Inc., EIA kits (MK118 and MK111, respectively, Bio Inc.,
Japan,). Total OC (tOC) was estimated as the sum of
cOC and ucOC [14]. Adiponectin and leptin were quan-
titatively determined using a commercially available en-
zyme immunoassay (EIA) kit from Boster (china). Serum
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DIAPLUS, USA); Fasting blood glucose (FBG) and 2-h
post-OGTT glucose were measured by auto-analyser
(Hitachi, USA); hemoglobin A1C (HbA1c) was measured
with HLC-723G8 (Tosoh Co., Tokyo, Japan) by high
performance liquid chromatography (HPLC). Insulin
resistance was calculated with HOMA-IR, which was
defined as: HOMA-IR = [FPS (mg/DL)*fasting insulin
(FINS (μU/ml)]/405. Basal insulin secretion which was
calculated by using the following formula HOMA-%
B:360*FINS(μU/ml)/(FPG-63) [15]. Quantitative insulin
sensitivity check index (QUICKI) were calculated on the
basis of suggested formulas: 1/[log (Insulin μU/ml) + log
(Glucose mg/DL)] [16].Statistical analyses
Data are expressed as means ± SDs. The normality
of data distribution was assessed by using the
Kolmogorov-Smirnov goodness-of-fit test. Two-factor
repeated-measures analysis of variance (ANOVA) was
used to test time*group interactions, with time and
treatment as factors. In case of a significant time*group
interaction, a between-group comparison of changes at
4 weeks was done by Independent-samples Student’s t
test analysis. When the time effect was significant, the
within-group comparison of values was performed by
the paired-samples t test. Differences in proportions
were evaluated by using a chi-square test. ANCOVA
was performed to examine the association between sup-
plementation group and measure of insulin sensitivity
and glucose. All statistical analyses were done by using
the Statistical Package for Social Sciences (SPSS version
16; SPSS Inc, Chicago, IL). The P < 0.05 was considered
significant.Table 1 General characteristics of premenopausal women wit
placebo
Placebo group (n = 4
Age (y) 40.09 ± 4.65
Weight (kg) at study baseline 71.09 ± 6.59
Weight (kg) at end of trial 71 ± 6.76
BMI (18.5-24.9 kg/m2) at study baseline 1(2.3%)
BMI (18.5-24.9 kg/m2) at the end of trial 2(4.7%)
BMI (25–29.9 kg/m2) ) at study baseline 42(97.7%)
BMI (25–29.9 kg/m2) at the end of trial 41(95.3%)
FM (%) at study baseline 38.55 ± 3.99
FM (%) at end of trial 38.57 ± 4.10
HbA1C (%) at study baseline 5.91 ± 0.49
All values are means ± SDs.
*Obtained from independent-samples t test.
**Obtained from chi-square test.Results and discussion
Results
The means and standard deviations for age, weight, and
BMI were 40.17 ± 4.9 years, 71 ± 6.5 kg, and 28.08 ± 1.65
kg/m2, respectively. Most of the women were overweight
and BMI distribution was not significantly different be-
tween two groups. According to the IPAQ questionnaire,
the both groups had the same low level of physical activ-
ity. Table 1 shows the baseline and end-of-trial character-
istics of the participants. Table 2 shows their dietary
intakes of relevant nutrients. No significant difference
existed between phylloquinone and placebo groups. Base-
line values of total osteocalcin, adiponectin, leptin, FBS, 2-
h post-OGTT glucose, fasting and 2-h post-OGTT insulin
have been shown in Table 3. The time effects were statisti-
cally significant on adiponectin, FBS, 2-h post-OGTT glu-
cose and 2-h post-OGTT insulin. Also the time*group
interaction effects on adiponectin and 2-h post-OGTT
glucose were significant (all P, 0.001). Intake of phyllo-
quinone supplement led to significant decrease in 2 h
post-OGTT glucose (−10.87 ± 27.41 compared with 1.20
± 18.63 mg/dl), 2 h post-OGTT insulin level (−17.46 ±
44.97 compared with 5.88 ± 23.65 μIU/ml) and a signifi-
cant increase in serum adiponectin concentration (1.24 ±
1.90 compared with −0.27 ± 1.08 μg/ml) compared with
placebo. We did not find any significant effect of phyllo-
quinone supplementation on total osteocalcin, leptin and
related glycemic and insulin variables. To evaluate the ef-
fect of each of the total osteocalcin and adiponectin on
the changes of glucose and insulin levels between groups,
we adjusted them for tOC and adiponectin (Table 4).
Discussions
Several epidemiological studies have investigated the as-
sociation between vitamin K intake and glycemic status.h PDM who received either vitamin K1 supplements or
3) Phylloquinone group (n = 39) P value
40.25 ± 5.32 0.88*
71.21 ± 6.47 0.93*





38.77 ± 3.86 0.79*
38.46 ± 4.05 0.90*
5.81 ± 0.64 0.42*





group (n = 39)
P value1
Energy (kcal/d) 1769 ± 275 1819 ± 272 0.42
Carbohydrate (g/d) 243.12 ± 37.76 249.60 ± 39.20 0.44
Protein (g/d) 75.04 ± 12.75 77.56 ± 11.60 0.35
Fat (g/d) 64.90 ± 10.05 66.32 ± 10.34 0.52
Vitamin k (μg/d) 57.16 ± 19.03 62.69 ± 15.45 0.15
Vitamin D (mg/d) 3.7 ± 1.6 4.06 ± 1.67 0.32
Calcium (mg/d) 719.38 ± 261 677.0 ± 237.97 0.44
All values are means ± SDs.
1Obtained from independent-samples t test.
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26–81 years of age, Yoshida et al. [7] showed that higher
intake of vitamin K was associated with better insulin
sensitivity and lower post-challenge glucose levels. In
addition, Beulens JW et al. [5], found that higher intakes
of vitamin K were associated with reduced risk of type 2
diabetes. In another study with similar results it was re-
ported in a National Health and Nutrition Examination
Survey (NHANES) 1999–2004 that vitamin K intake in
the highest, compared with the lowest, quintile was asso-
ciated with lower prevalence of hyperglycemia as a com-
ponent of metabolic syndrome [6]. However, the exact
mechanisms underlying the associations between vita-
min k intakes, glycemic status and insulin homeostasis
still remain unknown. One finding which could possibly
help shed light on the mechanism has been reported by
Lee et al. [3]. They demonstrated that osteocalcin, a
vitamin-K-dependent protein in bone, is involved in glu-
cose metabolism by increasing insulin secretion and cell
proliferation in pancreatic β-cells and by upregulating
the expression of the adiponectin gene in adipocytes,
thus improving insulin sensitivity. This study was de-
vised as a first study of its kind, to explore the impacts
of the carboxylation of Osteocalcin by vitamin K andTable 3 Metabolic variables, biomarkers of insulin resistance
and phylloquinone groups
Placebo group (n = 43)
Week0 Week4 Chang
Total Osteocalcin (ng/ml) 11.95 ± 5.76 12.08 ± 5.65 0.13 ±
leptin (ng/ml) 26.78 ± 10.33 25.62 ± 10.21 −1.15
Adiponectin (μg/ml) 8.81 ± 1.54 8.54 ± 1.87 −0.27
FBS (mg/DL) 106.69 ± 13.63 105.20 ± 12.41 −1.48
2-h-post-OGTT glucose (mg/DL) 155.27 ± 15.97 156.48 ± 26.44 1.20 ±
FINS (μIU/ml) 23.83 ± 12.08 23.80 ± 8.28 −0.02
2-h-post-OGTT INS (μIU/ml) 106.55 ± 46.96 112.43 ± 53.19 5.88 ±
All values are means ± SDs. *Different from week 0, P < 0.05; OGTT, oral glucose tole
1Obtained from independent-samples t test.the mediation effects of adiponectin in prediabetic, pre-
monopause women. In this study, it was observed that
phylloquinone supplementation for four weeks signifi-
cantly increased serum adiponectin, decreased 2-h
post-OGTT glucose and did not change the other re-
lated variables compared with placebo. In contrast,
Knapen MH [17] found that Supplementation with vita-
min K did not affect circulating adiponectin concentra-
tions. Choi et al. [18] also reported that no significant
alterations were seen in fasting plasma glucose and adi-
ponectin concentrations in serum with 4 weeks Vitamin
K2 Supplementation in healthy young male subjects.
Cross sectional studies have also pointed to the rela-
tionships between these variables. Kanazawa et al. [19]
found that that ucOC/OC ratio positively correlated
with serum adiponectin level in men. Reinehr T [20]
studied obese children and found no significant rela-
tionship between adiponectin and osteocalcin. Mean-
while, another study failed to show such an association
between adiponectin and osteocalcin [21].
In the current study, analysis of covariance was per-
formed to determine the role of either osteocalcin or
adiponectin in glucose and insulin homeostasis. It was
observed that adjustments for total steocalcin andand comparison of changes within and between placebo
Phylloquinone group (n = 39)
e Week0 Week4 Change P value1
1.85 14.50 ± 5.81 15.01 ± 6.51 0.50 ± 4.11 0.61
± 5.25 28.59 ± 9.61 28.29 ± 9.86 −0.29 ± 8.23 0.92
± 1.08 9.19 ± 1.80 10.44 ± 1.20* 1.24 ± 1.90 0.00
± 10.37 107.66 ± 10.72 104 ± 11.25* −3.12 ± 9.22 0.45
18.63 143.84 ± 35.30 132.97 ± 27.37* −10.87 ± 27.41 0.02
± 8.92 20.74 ± 9.90 20.56 ± 8.04 −0.18 ± 5.92 0.92
23.65 97.80 ± 54.50 80.34 ± 42.24* −17.46 ± 44.97 0.00
rance test; INS, Insulin; FINS, Fasting insulin; FBS, Fasting blood sugar.
Table 4 Adjusted changes in metabolic variables in





group (n = 39)
P value1
FBS (mg/DL)
Model1 1.48 ± 1.50 −3.12 ± 1.57 0.45
Model2 −1.46 ± 1.51 −3.13 ± 1.58 0.45
Model3 −1.97 ± 1.59 −2.59 ± 1.67 0.80
2-h post-OGTT
glucose (mg/DL)
Model1 1.20 ± 3.54 −10.87 ± 3.71 0.02
Model2 1.36 ± 3.54 −11.04 ± 3.71 0.01
Model3 2.48 ± 3.74 −12.28 ± 3.95 0.01
FINS (μIU/ml)
Model1 −0.02 ± 1.16 −0.18 ± 1.22 0.92
Model2 0.003 ± 1.17 −0.21 ± 1.23 0.89
Model3 -.039 ± 1.24 −0.16 ± 1.31 0.94
2-h post-OGTT insulin
(μIU/ml)
Model1 5.88 ± 5.40 −17.46 ± 5.67 0.00
Model2 5.69 ± 5.41 −17.25 ± 5.60 0.00
Model3 9.90 ± 5.58 −21.88 ± 5.89 0.00
HOMA-IR
Model1 −0.05 ± 0.32 −0.22 ± .34 0.76
Model2 -.05 ± 0.32 −0.22 ± 0.34 0.71
Model3 −0.06 ± 0.34 −0.20 ± 0.36 0.79
HOMA-B
Model1 −5.42 ± 14.49 14.95 ± 15.21 0.33
Model2 4.84 ± 14.50 14.31 ± 15.23 0.36
Model3 −7.10 ± 15.42 16.80 ± 16.28 0.31
QUICKI
Model1 −0.004 ± 0.002 −0.001 ± 0.002 0.43
Model2 −0.004 ± 0.002 −0.001 ± 0.002 0.44
Model3 −0.004 ± 0.002 −0.00 ± 0.003 0.33
All values are means ± SEs. Model 1 show original raw data, Model 2 was
adjusted for tOC; Model 3 was adjusted for adiponectin; tOC, Total osteocalcin;
FBS, Fasting blood sugar; OGTT, Oral glucose tolerance test; FINS, Fasting
insulin; HOMA-IR, Homeostasis model assessment insulin resistance index;
HOMA-B, Homeostatic model assessment–β cell function; QUICKI, Quantitative
insulin sensitivity check index. 1Obtained from ANCOVA.
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variables to glycemic status. Along the same lines, Shea
et al. [22] reported that the strength of the association
between total osteocalcin and carboxylated osteocalcin
with HOMA-IR was somewhat attenuated after adiponec-
tin was accounted for; therefore, they concluded that the
association between total osteocalcin and carboxylated
osteocalcin with HOMA-IR may depend partially on
adiponectin. Chen X et al. [23] reported that the nega-
tive association between HOMA-IR and tOC remainedsignificant after being controlled for adiponectin. In
Hwang YC et al. study [24] on adult subjects, it was re-
ported that although the circulating osteocalcin level
was associated with improved glucose tolerance and in-
sulin secretion, this was independent of the plasma adi-
ponectin level.
Although these studies and their contradictory results
have considered the relationships between adiponectin
and osteocalcin, it seems vitamin K probably influence
Glycemic status through other mechanisms.
Conclusions
Finally although this study could not provide the under-
lying mechanism we speculate that vitamin K1 supple-
mentation could modulate glycemic status by mechanism
other total osteocalcin and adiponectin in premonopausal
prediabetes women. In conclusion our study demon-
strated that phylloquinone supplementation improved
glycemic status in premenopausal prediabetic women
independent of adiponectin.
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